Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CODX Stock Forecast 2026-2027
$2.46
Current Price
$9.18M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CODX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CODX Price Momentum
-5.7%
1 Week Change
-27.0%
1 Month Change
-70.7%
1 Year Change
-51.5%
Year-to-Date Change
-94.7%
From 52W High of $46.50
+95.2%
From 52W Low of $1.26
📊 TOP ANALYST CALLS
Did CODX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Co-Diagnostics is one of their latest high-conviction picks.
Latest CODX Stock Price Targets & Analyst Predictions
CODX has shown a year-to-date change of -51.5% and a 1-year change of -70.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CODX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CODX Analyst Ratings
0
Buy
1
Hold
0
Sell
CODX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.46
Latest CODX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CODX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 23, 2026 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
| Nov 26, 2025 | Maxim Group | Buy | Initiates | $N/A | |
| Nov 24, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Oct 28, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 16, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 19, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 17, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 28, 2025 | D. Boral Capital | Buy | Initiates | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Jun 17, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| May 13, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Mar 15, 2024 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Dec 29, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 13, 2023 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Aug 14, 2023 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| May 15, 2023 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Mar 20, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $N/A |
Co-Diagnostics Inc. (CODX) Competitors
The following stocks are similar to Co-Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CODX
Co-Diagnostics
mkt cap
9.55M
Co-Diagnostics Inc. (CODX) Financial Data
Co-Diagnostics Inc. has a market capitalization of $9.18M with a P/E ratio of -0.1x. The company generates $718,166 in trailing twelve-month revenue with a 64.3% profit margin.
Revenue growth is +190.3% quarter-over-quarter, while maintaining an operating margin of -6,309.1% and return on equity of -151.7%.
Valuation Metrics
Market Cap
$9.18M
Enterprise Value
$3.20M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
13.3x
Growth & Margins
Revenue Growth (YoY)
+190.3%
Gross Margin
-32.8%
Operating Margin
-6,309.1%
Net Margin
+64.3%
EPS Growth
+190.3%
Financial Health
Cash/Price Ratio
+92.9%
Current Ratio
2.3x
Debt/Equity
12.7x
ROE
-151.7%
ROA
-52.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Co-Diagnostics Inc. (CODX) Business Model
About Co-Diagnostics Inc.
What They Do
Develops molecular diagnostics and PCR testing solutions.
Business Model
The company generates revenue by developing, manufacturing, and selling reagents for diagnostic tests that leverage nucleic acid detection. Its Co-Dx PCR platform is designed for rapid testing of infectious diseases, enabling both point-of-care and at-home testing, thereby catering to a wide range of healthcare needs.
Additional Information
Co-Diagnostics Inc. is involved in various sectors including healthcare, oncology, and agriculture, focusing on accessible diagnostics. The company also has a joint venture in India that enhances decentralized PCR testing, which may expand its market reach. Founded in 2013 and based in Salt Lake City, Utah, it continues to innovate in the molecular diagnostics space.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
115
CEO
Mr. Dwight H. Egan
Country
United States
IPO Year
2017
Website
co-dx.comCo-Diagnostics Inc. (CODX) Latest News & Analysis
Latest News
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
9 days ago
Quick Summary
Co-Diagnostics, Inc. will participate in a UN workshop in Bangkok on July 8-10, 2026, focusing on near-point-of-care TB diagnostics to advance WHO guidelines and support national programs.
Why It Matters
Co-Diagnostics' participation in a UN workshop on TB diagnostics could enhance its market position and revenue potential, signaling growth opportunities in a critical healthcare sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. completed clinical studies for its Co-Dx PCR Flu A/B & RSV test, enrolling over 1,400 patients. A 510(k) and CLIA Waiver submission to the FDA is planned for Q3 2026.
Why It Matters
The completion of clinical studies and impending FDA submissions could lead to new product approvals for Co-Diagnostics, potentially boosting revenue and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. has expanded its mosquito abatement district customer base to 21 states, adding four new lab installations in June, coinciding with a webinar for potential customers.
Why It Matters
Co-Dx's expansion into 21 states and new laboratory installations indicate strong demand for its products, potentially boosting revenue and market share in the growing mosquito control sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics has signed an exclusive distribution agreement in Mexico for its Co-Dx™ PCR Pro® platform, expanding its presence in Latin America ahead of regulatory approval for market launch.
Why It Matters
The exclusive distribution agreement in Mexico enhances Co-Diagnostics' market presence, potentially boosting sales and growth in Latin America, which can positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Co-Diagnostics, Inc. is advancing its Ebola PCR development with CoSara Diagnostics, enhancing its Co-Dx™ platform for outbreak response and surveillance.
Why It Matters
Co-Diagnostics' advancement in Ebola testing enhances its product offerings and positions the company favorably in the diagnostics market, potentially boosting investor confidence and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The WHO declared a Public Health Emergency of International Concern for the Bundibugyo virus Ebola outbreak on May 17, 2026, signaling a significant shift in the biodefense landscape.
Why It Matters
The PHEIC declaration highlights heightened demand for biodefense investments, potentially boosting stocks in healthcare and pharmaceutical sectors focused on outbreak response and vaccine development.
Source: MarketBeat
Market Sentiment:
Neutral
Frequently Asked Questions About CODX Stock
What is Co-Diagnostics Inc.'s (CODX) stock forecast for 2027?
Analyst forecasts for Co-Diagnostics Inc. (CODX) are not currently available. The stock is trading at $2.46.
Is CODX stock a good investment in 2027?
According to current analyst ratings, CODX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CODX stock?
Price predictions from Wall Street analysts for CODX are not currently available. The stock is trading at $2.46.
What is Co-Diagnostics Inc.'s business model?
The company generates revenue by developing, manufacturing, and selling reagents for diagnostic tests that leverage nucleic acid detection. Its Co-Dx PCR platform is designed for rapid testing of infectious diseases, enabling both point-of-care and at-home testing, thereby catering to a wide range of healthcare needs.
What is the highest forecasted price for CODX Co-Diagnostics Inc.?
Price targets from Wall Street analysts for CODX are not currently available. The stock is trading at $2.46.
What is the lowest forecasted price for CODX Co-Diagnostics Inc.?
Price targets from Wall Street analysts for CODX are not currently available. The stock is trading at $2.46.
What is the overall CODX consensus from analysts for Co-Diagnostics Inc.?
The overall analyst consensus for CODX is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CODX stock price projections?
Stock price projections, including those for Co-Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:16 AM UTC